ReviewBeyoglu eye journal2024
Efficacy and Safety of Topical Tacrolimus for Vernal Keratoconjunctivitis: A Systematic Review.
Review in Beyoglu eye journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The impact of tacrolimus therapy on the outcomes of vernal keratoconjunctivitis: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Vernal keratoconjunctivitis (VKC) poses a significant challenge in ocular inflammation management, necessitating potent anti-inflammatory interventions. Despite its restricted utilization, tacrolimus has emerged as a promising agent in inflammation control. However, the specific efficacy of topical tacrolimus in VKC remains underexplored. Methods: A systematic review was conducted to evaluate the impact of topical tacrolimus on VKC, adhering meticulously to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Relevant studies were meticulously retrieved from comprehensive databases including Cochrane Library, PubMed, EBSCO Host, ProQuest, and Google Scholar, with a focus on English-language publications. This systematic review protocol was prospectively registered with PROSPERO (CRD42022302291). Results: The review encompassed 11 studies involving 607 participants, with an average age of 8.45 years. Tacrolimus concentrations utilized in the interventions spanned from 0.005% to 0.1%, delivered through eye ointment or drops. Across the studies, topical tacrolimus demonstrated significant reductions in both the total objective signs score and total subjective symptoms score. Adverse events reported encompassed sensory experiences such as burning sensation, ocular stinging, pain, redness, and sporadic photophobia. Conclusion: This systematic review underscores the notable efficacy of topical tacrolimus in ameliorating the clinical manifestations and symptomatic burden associated with VKC. Furthermore, tacrolimus exhibited a favorable safety profile, with minor adverse effects reported infrequently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.